Drugs / SCH 900776
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00907517 | Jul 2009 → Jun 2011 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00779584 | Oct 2008 → May 2011 | Hodgkins lymphoma, non-Hodgkin lymphoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01870596 | May 2013 → Dec 2014 | acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent +8 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCH 900776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01870596 ↗ |
| Known as | MK-8776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00907517 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL2386889 ↗1“Chk1 inhibitor SCH 900776” NCT01870596 ↗ |
| Modality | Small molecule | — CHEMBL2386889 ↗ |
| Route | Intravenous | “IV infusion” NCT00779584 ↗ |
| Target | CHEK1 | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL2386889 ↗ |